| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_chr2_0528400 | Intergenic-Intergenic | chr2:217525335-217526664 | chr2:216660612-216661941 | 175 nt | 0.6457 |
| hsa_IGFBP2_0000700 | Exon-Exon | chr2:217525362-217526721 | chr2:216660639-216661998 | 148 nt | 0.6486 |
| hsa_IGFBP2_0000800 | Exon-Exon | chr2:217525420-217526607 | chr2:216660697-216661884 | 117 nt | 0.6410 |
| hsa_chr2_0528500 | Intergenic-Intergenic | chr2:217525435-217526664 | chr2:216660712-216661941 | 159 nt | 0.6604 |
| hsa_IGFBP2_0000900 | Exon-Exon | chr2:217525509-217526570 | chr2:216660786-216661847 | 1062 nt | 0.5395 |
| hsa_chr2_0528600 | Intergenic-Intergenic | chr2:217528759-217528980 | chr2:216664036-216664257 | 222 nt | 0.6081 |
| hsa_chr2_0528700 | Intergenic-Intergenic | chr2:217528812-217529018 | chr2:216664089-216664295 | 207 nt | 0.6184 |
| hsa_IGFBP2_0001000 | Exon-Exon | chr2:217528886-217529079 | chr2:216664163-216664356 | 194 nt | 0.5825 |
A study in humans demonstrated that circIGFBP2 is significantly increased in serum exosomes of patients with metastatic pancreatic cancer, where its levels correlate with TNM stages and poor prognosis [Misir et al. DOI:10.1038/s41418-022-00948-7].